Nuclea Biotechnologies Inc. of Worcester and Pittsfield is joining with Boston Medical Center in an effort to develop treatments for breast and prostate cancers.
Nuclea will pay BMC about $1.4 million to support research at the hospital, and Nuclea will have right of first refusal for the commercialization of new discoveries.
Nuclea develops “biomarkers” and diagnostic systems to predict which treatments will be effective for which patient, depending on their genetic makeup.
The partnership will involve joint research between the hospital’s Department of Pathology and Laboratory Medicine and its Department of Radiology. It will also allow for clinical trials in and around Boston.
